Arca
Skip to content
Tools
Tools

PIK3CA: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides.

  • Drugs that act on it: 8
  • Approved: 3
  • In phases 1 to 3: 5
  • Sponsors: 6

Who is on it, and how far along

Every drug ChEMBL records acting on PIK3CA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 7
  • Other 1

Approved3

  • Alpelisib
  • Inavolisib
  • Copanlisib

Phase 30

    Phase 22

    • Serabelisib
    • Fimepinostat

    Phase 13

    • BAY-1082439
    • PKI-179
    • PWT-33579

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Curis, Inc.113%
    • Wyeth is now a wholly owned subsidiary of Pfizer113%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: PI3-kinase p110-alpha subunit inhibitor.
    AlpelisibApprovedNovartis PharmaceuticalsSmall moleculeInhibitor45
    InavolisibApprovedRocheSmall moleculeInhibitor32
    CopanlisibApprovedBayerSmall moleculeInhibitor15
    SerabelisibPhase 2Faeth TherapeuticsSmall moleculeInhibitor2
    FimepinostatPhase 2Curis, Inc.Small moleculeInhibitor1
    BAY-1082439Phase 1BayerSmall moleculeInhibitor0
    PKI-179Phase 1Wyeth is now a wholly owned subsidiary of PfizerSmall moleculeInhibitor0
    PWT-33579Phase 1—OtherInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 27 in all, from ClinicalTrials.gov.
    Oral GDC-0077 in Premature Ovarian InsufficiencyInavolisibPhase 1Not yet recruitingWomen's Hospital School Of Medicine Zhejiang UniversityOct 29, 2026
    Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient AdherenceInavolisib—RecruitingTianjin Medical University Cancer Institute and HospitalSep 14, 2026
    Alpelisib Challenge Test (ACT)AlpelisibPhase 1RecruitingColumbia UniversityAug 21, 2026
    A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular AnomaliesAlpelisib—Not yet recruitingNovartis PharmaceuticalsAug 17, 2026
    A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesInavolisibPhase 2RecruitingHoffmann-La RocheAug 5, 2026
    A Multicenter, Single Arm Study to Evaluate the Preliminary Efficacy and Safety Profile of Inavolisib in Previously Treated Pancreatic Ductal Adenocarcinoma PatientsInavolisibPhase 2Not yet recruitingFudan UniversityJul 10, 2026
    Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.AlpelisibPhase 2Not yet recruitingNovartis PharmaceuticalsJul 1, 2026
    EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)Alpelisib—RecruitingTel-Aviv Sourasky Medical CenterJun 12, 2026
    A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.InavolisibPhase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityJun 1, 2026
    Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and ChemotherapyAlpelisibPhase 2Not yet recruitingWen-zhao ZHONGMay 7, 2026
    Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast CancerSerabelisibPhase 1 / Phase 2RecruitingFaeth TherapeuticsApr 30, 2026
    24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAsAlpelisibPhase 2RecruitingChildren's Hospital of PhiladelphiaApr 22, 2026
    A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast CancerInavolisib—Not yet recruitingxuliangApr 21, 2026
    Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4InavolisibPhase 2Not yet recruitingNational Cancer Institute, NaplesApr 13, 2026
    A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA MutationInavolisibPhase 2Not yet recruitingHu HaiMar 2, 2026
    EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)AlpelisibPhase 2RecruitingNovartis PharmaceuticalsMay 30, 2025
    Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsAlpelisibPhase 1 / Phase 2RecruitingEnsem TherapeuticsMay 29, 2025
    Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial CancerSerabelisibPhase 2RecruitingFaeth TherapeuticsJun 17, 2024
    Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)CopanlisibPhase 2Active, not recruitingNational Cancer Institute (NCI)May 6, 2024
    Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)CopanlisibPhase 2Active, not recruitingNational Cancer Institute (NCI)Apr 11, 2024
    Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing DiseaseFimepinostatPhase 2RecruitingUniversity of California, Los AngelesAug 2, 2023
    Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)CopanlisibPhase 2Active, not recruitingNational Cancer Institute (NCI)Aug 8, 2022
    Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaCopanlisibPhase 1 / Phase 2Active, not recruitingCity of Hope Medical CenterJun 25, 2021
    Copanlisib Plus Venetoclax in R/R DLBCLCopanlisibPhase 1 / Phase 2Active, not recruitingDana-Farber Cancer InstituteOct 1, 2020
    Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerCopanlisibPhase 1 / Phase 2Active, not recruitingNational Cancer Institute (NCI)Apr 15, 2020
    Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENCopanlisibPhase 1 / Phase 2Active, not recruitingNational Cancer Institute (NCI)Mar 23, 2020
    A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerCopanlisibPhase 1 / Phase 2Active, not recruitingBrown UniversityFeb 5, 2020

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Megalencephaly-capillary malformation-polymicrogyria syndrome0.85
    • CLOVES syndrome0.80
    • PIK3CA-related overgrowth spectrum0.77
    • Cowden syndrome 50.75
    • Seborrheic keratosis0.73
    • Breast adenocarcinoma0.73
    • CLAPO syndrome0.72
    • Pik3ca related overgrowth spectrum0.72
    • Megalodactyly0.68

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4005, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P42336, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.